Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S. Baselga J, et al. J Clin Oncol. 2009 Feb 1;27(4):526-34. doi: 10.1200/JCO.2007.14.2646. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075286 Clinical Trial.
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.
Bartsch R, Pérez-García JM, Furtner J, Berghoff AS, Marhold M, Starzer AM, Hughes M, Kabraji S, Sammons S, Anders C, Murthy RK, Van Swearingen AED, Pereslete A, Gion M, Vaz Batista M, Braga S, Pinto PBC, Sampayo-Cordero M, Llombart-Cussac A, Preusser M, Cortés J, Lin NU. Bartsch R, et al. Among authors: llombart cussac a. ESMO Open. 2025 Jan;10(1):104092. doi: 10.1016/j.esmoop.2024.104092. Epub 2025 Jan 3. ESMO Open. 2025. PMID: 39754978 Free PMC article.
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).
Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: llombart cussac a. Ann Oncol. 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.12.010. Online ahead of print. Ann Oncol. 2024. PMID: 39706338 Free article.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, García Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruíz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Jhaveri KL, et al. Among authors: llombart cussac a. N Engl J Med. 2024 Dec 11. doi: 10.1056/NEJMoa2410858. Online ahead of print. N Engl J Med. 2024. PMID: 39660834
Moving toward response-adapted trials in oncology.
Pérez-García J, Antonarelli G, Gion M, Llombart-Cussac A, Cortés J. Pérez-García J, et al. Among authors: llombart cussac a. Nat Med. 2024 Dec;30(12):3426-3428. doi: 10.1038/s41591-024-03346-3. Nat Med. 2024. PMID: 39528666 No abstract available.
Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.
Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J. Cortés A, et al. Among authors: llombart cussac a. Breast. 2024 Dec;78:103834. doi: 10.1016/j.breast.2024.103834. Epub 2024 Nov 3. Breast. 2024. PMID: 39520738 Free PMC article. Clinical Trial.
146 results